Trial Profile

JAK Inhibitor Prior to Allogeneic Stem Cell Transplant for Patients With Primary and Secondary Myelofibrosis: A Prospective Study

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 08 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ruxolitinib (Primary) ; Busulfan; Cyclophosphamide; Fludarabine; Melphalan; Methotrexate; Mycophenolate mofetil; Mycophenolate mofetil; Tacrolimus; Tacrolimus
Indications Graft-versus-host disease; Myelofibrosis
Focus Therapeutic Use

Most Recent Events

17 Jun 2022 Status changed from recruiting to active, no longer recruiting.
13 Dec 2021 Planned End Date changed from 11 Jun 2026 to 28 Dec 2025.
13 Dec 2021 Planned primary completion date changed from 11 Dec 2023 to 28 Dec 2022.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com